Premium
Escitalopram in the treatment of anxiety symptoms associated with depression
Author(s) -
Bandelow Borwin,
Andersen Henning F.,
Dolberg Ornah T.
Publication year - 2006
Publication title -
depression and anxiety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.634
H-Index - 129
eISSN - 1520-6394
pISSN - 1091-4269
DOI - 10.1002/da.20141
Subject(s) - escitalopram , psychology , anxiety , psychiatry , hamilton anxiety rating scale , citalopram , somatization , placebo , major depressive disorder , clinical psychology , antidepressant , population , rating scale , mood , medicine , developmental psychology , alternative medicine , environmental health , pathology
Most patients with depression have symptoms of anxiety associated with their illness. Our aim in this study was to investigate the efficacy of escitalopram, a proven antidepressant, on symptoms of anxiety in patients with major depressive disorder (MDD). Data from five placebo‐controlled escitalopram studies in MDD were analyzed. Three of the studies also included a comparison with citalopram. In all studies, anxiety was assessed using the Inner Tension item (item 3) of the Montgomery–Åsberg Depression Rating Scale (MADRS). In three studies, anxiety symptoms were also specifically assessed, either continuously over time or at baseline and end point, by using the Hamilton Rating Scale for Anxiety (HAM‐A), the Anxious Mood item of the HAM‐A (item 1), the Psychic Anxiety subscale of the HAM‐A (items 1‐6 and 14), the Anxiety Psychic item (item 10) of the Hamilton Rating Scale for Depression (HAM‐D‐24), and the Anxiety/Somatization subfactor (items 10–13, 15, and 17) of the HAM‐D‐24. Escitalopram was significantly superior to placebo in all comparisons. Citalopram was also consistently better than placebo in all comparisons, except in the HAM‐D‐24 Anxiety/Somatization subfactor. In some comparisons with placebo, escitalopram showed a significantly earlier onset of action or an earlier separation. Escitalopram was significantly more effective compared to placebo in treating both anxiety symptoms and the entire depression in the total depressive population, as well as in depressive patients with a high degree of anxiety. Depression and Anxiety 24:53–61, 2007. © 2006 Wiley‐Liss, Inc.